New Zealand markets closed
  • NZX 50

    11,382.56
    +60.85 (+0.54%)
     
  • NZD/USD

    0.6252
    -0.0011 (-0.18%)
     
  • NZD/EUR

    0.6006
    -0.0003 (-0.06%)
     
  • ALL ORDS

    7,447.60
    +15.40 (+0.21%)
     
  • ASX 200

    7,259.50
    +17.70 (+0.24%)
     
  • OIL

    76.28
    -1.66 (-2.13%)
     
  • GOLD

    1,754.00
    +8.40 (+0.48%)
     
  • NASDAQ

    11,756.03
    -82.68 (-0.70%)
     
  • FTSE

    7,486.67
    +20.07 (+0.27%)
     
  • Dow Jones

    34,347.03
    +152.97 (+0.45%)
     
  • DAX

    14,541.38
    +1.82 (+0.01%)
     
  • Hang Seng

    17,573.58
    -87.32 (-0.49%)
     
  • NIKKEI 225

    28,283.03
    -100.06 (-0.35%)
     
  • NZD/JPY

    86.9410
    +0.2080 (+0.24%)
     

McDonough to lead SwRI’s Chemistry and Chemical Engineering Division

SwRI’s multidisciplinary staff conducts R&D for government, industry clients worldwide

SAN ANTONIO, October 03, 2022--(BUSINESS WIRE)--Dr. Joe McDonough has been named vice president of Southwest Research Institute’s Chemistry and Chemical Engineering Division. McDonough previously served as director of the division’s Pharmaceuticals and Bioengineering Department.

"I am privileged to step into this role to lead SwRI’s Chemistry and Chemical Engineering Division," McDonough said. "The Institute has a longstanding legacy as pioneers and visionaries in the chemistry field. We have an exceptional staff working to advance technologies in multiple disciplines."

The Chemistry and Chemical Engineering Division is one of SwRI’s longest-running organizations, with chemistry and related technologies being a research focus since its founding in 1947. As vice president, McDonough will oversee a staff of more than 200, working in five departments: Analytical and Environmental Chemistry, Chemical Engineering, Fire Technology, Geosciences and Engineering, and Pharmaceuticals and Bioengineering.

"Our staff continues to innovate and expand capabilities to meet changing clients’ needs," McDonough said. "In keeping with SwRI’s mission, we will continue to innovate and expand our research programs and transition technologies to the marketplace. We will remain at the forefront for our clients, providing new discoveries, high-impact advanced development and critical analyses."

McDonough joined the Institute in 2000 and was appointed director of SwRI’s Pharmaceuticals and Bioengineering Department in 2008. Under McDonough’s leadership, the department has grown its microencapsulation, formulation and clinical supply of pharmaceuticals and vaccine development programs, integrating Good Manufacturing Practices and ISO quality measures. McDonough leads a chemical weapons medical countermeasures program, developing a cyanide antidote licensed for clinical development as well as a vaccine for tularemia, a potential biothreat. His team is developing treatments for filovirus, type 1 diabetes, COVID-19 and other emerging threats as well as a controlled-release steroid formulation that has been licensed for commercialization.

For more information, visit https://www.swri.org/technical-divisions/chemistry-chemical-engineering.

About SwRI:

SwRI is an independent, nonprofit, applied research and development organization based in San Antonio, Texas, with more than 3,000 employees and an annual research volume of nearly $726 million. Southwest Research Institute and SwRI are registered marks in the U.S. Patent and Trademark Office. For more information, please visit www.swri.org.

https://www.swri.org/press-release/mcdonough-lead-swri-chemistry-chemical-engineering-division

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005072/en/

Contacts

Tracey M.S. Whelan • (210) 522-2256 or twhelan@swri.org